BPX-601 (GoCAR-T) and BPX-701 (TCR)
We have initiated Phase 1 trials of BPX-601 and BPX-701 at centers in the U.S. Patient recruitment is ongoing, and we anticipate reporting initial results for both in 2018.
BPX-601 is our novel GoCAR-T, our first clinical candidate incorporating our proprietary iMC activation switch. This novel construct is designed to give physicians control over the level and persistence of stimulation and proliferation of these cancer fighting cells for improved efficacy and safety. BPX-601 targets tumors expressing prostate stem cell antigen, or PSCA, and our Phase 1 trial is being conducted in nonresectable pancreatic cancer.
BPX-701 is a high affinity T cell receptor product candidate designed with our CaspaCIDe® safety switch. It is being tested in a Phase 1 study of patients with refractory or relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who test positive for PRAME, or preferentially expressed antigen in melanoma.